Cargando…

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in

Detalles Bibliográficos
Autor principal:	Blann, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548753/ https://www.ncbi.nlm.nih.gov/pubmed/26316773 http://dx.doi.org/10.2147/VHRM.S89736

Ejemplares similares

Tackling Nonatrial Fibrillation Diseases Using Nonvitamin K Antagonist Oral Anticoagulant: by What and for Whom?
por: Kim, Jong S.
Publicado: (2019)

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
por: Brown, Karen S., et al.
Publicado: (2016)

Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants
por: Morimoto, Yoshinari, et al.
Publicado: (2016)

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
por: Turpie, Alexander G.G., et al.
Publicado: (2017)

Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
por: Sarah, Lessire, et al.
Publicado: (2014)

Erratum to “Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants”
por: Lessire, Sarah, et al.
Publicado: (2014)

Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants
por: Gallù, Mariacarla, et al.
Publicado: (2020)

The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Consideration of NOACs (novel or non-vitamin K-dependent oral anticoagulants) in dental procedure
por: Song, Jiyoung
Publicado: (2021)

Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment
por: Wilke, Thomas, et al.
Publicado: (2019)

Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection
por: Mustanoja, Satu, et al.
Publicado: (2015)

Real‐world use of nonvitamin K antagonist oral anticoagulant in atrial fibrillation patients with liver disease: A meta‐analysis
por: Dai, Qixin, et al.
Publicado: (2020)

A Comparison among Nonvitamin K Antagonist Oral Anticoagulants in Asian Patients with Venous Thromboembolism: A Multi-Institutional Study
por: Tsai, Ming-Lung, et al.
Publicado: (2022)

The change of renal functions after nonvitamin K oral anticoagulants in patients with atrial fibrillation
por: Chantrarat, Thoranis, et al.
Publicado: (2021)

Difference between the Upper and the Lower Gastrointestinal Bleeding in Patients Taking Nonvitamin K Oral Anticoagulants
por: Maruyama, Kyohei, et al.
Publicado: (2018)

Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity‐Weighted Cohort Study
por: Søgaard, Mette, et al.
Publicado: (2019)

Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction
por: Singh, Balbir, et al.
Publicado: (2022)

Nonvitamin K oral anticoagulants with proton pump inhibitor cotherapy ameliorated the risk of upper gastrointestinal bleeding
por: Chaiyana, Parata, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure: A case report
por: Shen, Long, et al.
Publicado: (2018)

Erratum to: Practice-derived data on Non-vitamin K antagonist Oral Anticoagulant (NOAC) therapy to complement observations from randomized trials
Publicado: (2020)

Assessment of treatment patterns and patient awareness in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants (ASPECT-NOAC)
por: Badak, Özer, et al.
Publicado: (2022)

The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study
por: Grymonprez, M, et al.
Publicado: (2023)

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a dedicated NOAC clinic
por: de Veer, A. J. W. M., et al.
Publicado: (2019)

Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study
por: Han, Sola, et al.
Publicado: (2021)

Abstract 28. Novel Oral Anticoagulants (NOACs) in Microsurgery: A Review
por: Yao, Amy, et al.
Publicado: (2017)

Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
por: Altman, Raul, et al.
Publicado: (2014)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Assessing Adherence and Persistence to Non-vitamin K Antagonist Oral Anticoagulants (NOACs) among Patients with Atrial Fibrillation in Tertiary-care Referral Centers in Malaysia
por: Kubas, Mohammed A, et al.
Publicado: (2020)

Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis
por: Caso, Valeria, et al.
Publicado: (2023)

New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study
por: Altay, Servet, et al.
Publicado: (2017)

A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)
por: Lindahl, Tomas L., et al.
Publicado: (2017)

Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
por: Wu, Olivia, et al.
Publicado: (2022)

The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey
por: Potpara, Tatjana S., et al.
Publicado: (2017)

Tranexamic Acid for Intracerebral Hemorrhage in Patients on Non-Vitamin K Antagonist Oral Anticoagulants (TICH-NOAC): A Multicenter, Randomized, Placebo-Controlled, Phase 2 Trial
por: Polymeris, Alexandros A., et al.
Publicado: (2023)

Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population‐based propensity‐weighted cohort study
por: Rodríguez‐Bernal, Clara L., et al.
Publicado: (2020)

Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation
por: Lau, Yee Cheng, et al.
Publicado: (2016)

Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS(2) score ⩾ 2
por: Fernandez, Maria M, et al.
Publicado: (2015)

The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis
por: Udayachalerm, Sariya, et al.
Publicado: (2018)

Oral anticoagulation following bioprosthetic SAVR in patients with atrial fibrillation: what’s the current status of NOACs?
por: Milojevic, Milan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_drj0j3g1hcfkog68dggn3q42is